Joshua Cabral
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua Cabral has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
Adam Metwalli
2 shared publicationsEric Otto
2 shared publicationsSteven Nagel
2 shared publications- Aalya Hamouda
Division of Urology McGill University Montreal QC Canada
1 shared publication Abby S. Taylor
1 shared publication- Abdulla Alameeri
Division of Urology McGill University Montreal QC Canada
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1171-1179
Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study
Objective: Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). Materials and Methods: We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal–Wallis tests. Finally, exploratory sub‐analyses were performed in the salvage therapy group based on the type of prior BPH intervention. Results: Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30‐day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post‐void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. Conclusion: We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.
- 7 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1171-1179
Open AccessAquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study
Objective: Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). Materials and Methods: We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal–Wallis tests. Finally, exploratory sub‐analyses were performed in the salvage therapy group based on the type of prior BPH intervention. Results: Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30‐day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post‐void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. Conclusion: We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.
- Open Access
- 29 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1083-1090
Prostate Cancer, Genetic Susceptibility, and Risk of Chronic Non‐Urological Complications
Background: Chronic nonurological complications are common among prostate cancer (PCa) survivors; however, their spectrum, magnitude, and genetic contribution remain poorly characterized. Methods: We evaluated 15 commonly reported nonurological complications and tested their associations with exposure to PCa and disease‐specific polygenic risk scores (PRS) in the UK Biobank (UKB; N = 219,133). Analyses were conducted using cause‐specific Cox proportional‐hazards models within a full‐cohort framework with time‐updated PCa status, delayed entry at study recruitment, and age as the underlying time scale. Results: After recruitment, incident PCa was diagnosed in 13,780 men, of which 1,656 (12.02%) had metastatic PCa (mPCa). Risks for seven complications were higher among men with PCa, adjusting for genetic background (all p < 0.05), including osteoporosis, venous thromboembolism, depression, and four primary cancers (bladder, kidney, colorectal, and pancreatic). Risks were consistently stronger among men exposed to mPCa than non‐mPCa; for example, the hazard ratio (HR) (95% confidence interval) for osteoporosis was 1.88 (1.63–2.18) for any PCa, 4.67 (3.11–7.01) for mPCa, and 1.75 (1.50–2.04) for non‐mPCa. Elevated risks for three additional complications (coronary artery disease, type 2 diabetes and chronic obstructive pulmonary disease) were observed only among men with mPCa. The risks for these ten complications were further increased among men with higher disease‐specific PRS; for example, the HR for osteoperosis in mPCa patients in the top PRS quartile was 13.57 (8.24–22.34) compared with men without PCa ( p < 0.001). Conclusion: PCa diagnosis and inherited genetic susceptibility jointly contribute to increased risks of multiple chronic non‐urological complications among survivors.
- 29 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1083-1090
Open AccessProstate Cancer, Genetic Susceptibility, and Risk of Chronic Non‐Urological Complications
Background: Chronic nonurological complications are common among prostate cancer (PCa) survivors; however, their spectrum, magnitude, and genetic contribution remain poorly characterized. Methods: We evaluated 15 commonly reported nonurological complications and tested their associations with exposure to PCa and disease‐specific polygenic risk scores (PRS) in the UK Biobank (UKB; N = 219,133). Analyses were conducted using cause‐specific Cox proportional‐hazards models within a full‐cohort framework with time‐updated PCa status, delayed entry at study recruitment, and age as the underlying time scale. Results: After recruitment, incident PCa was diagnosed in 13,780 men, of which 1,656 (12.02%) had metastatic PCa (mPCa). Risks for seven complications were higher among men with PCa, adjusting for genetic background (all p < 0.05), including osteoporosis, venous thromboembolism, depression, and four primary cancers (bladder, kidney, colorectal, and pancreatic). Risks were consistently stronger among men exposed to mPCa than non‐mPCa; for example, the hazard ratio (HR) (95% confidence interval) for osteoporosis was 1.88 (1.63–2.18) for any PCa, 4.67 (3.11–7.01) for mPCa, and 1.75 (1.50–2.04) for non‐mPCa. Elevated risks for three additional complications (coronary artery disease, type 2 diabetes and chronic obstructive pulmonary disease) were observed only among men with mPCa. The risks for these ten complications were further increased among men with higher disease‐specific PRS; for example, the HR for osteoperosis in mPCa patients in the top PRS quartile was 13.57 (8.24–22.34) compared with men without PCa ( p < 0.001). Conclusion: PCa diagnosis and inherited genetic susceptibility jointly contribute to increased risks of multiple chronic non‐urological complications among survivors.
- 4 October 2024
- Published by Elsevier
- p. 333-335
FDA overview
- 4 October 2024
- Published by Elsevier
List of contributors